BAM Logo



EPTIS factsheet 1144070 | Last revision 2024-05-22 | URL: https://www.eptis.bam.de/pts1144070 https://www.eptis.bam.de/pts1144070

PT provider
PT provider Weqas Weqas
Based in United Kingdom
Language(s) English
Remarks The Programme aims to assess the performance of organisations utilising biochemical markers to aid in the diagnosis of pre-eclampsia in pregnancy. The programme aim is to cover the clinically relevant range, i.e. PlGF < 12 pg/ml to ≥100 pg/ml and sFlt-1/PlGF ratio of < 33 to > 110. However, the analytical measuring range will also be assessed where appropriate. The programme is suitable for both Laboratory and POCT applications. Three liquid human samples are distributed monthly, with a minimum of 36 samples distributed over the year covering a wide clinically relevant range. The samples consist of endogenous samples from patients along with a panel of linearly related samples produced from donations from healthy volunteers spiked with PlGF and sFlt-1. They are distributed on a number of occasions over that period which allows for the assessment of the organisation’s and method’s performance, including linearity, bias, within and between batch imprecision. Post – analytical interpretation of pre-eclampsia risk outcome is also assessed. Key Features: - Samples cover analytical and clinical range for sFlt-1 & PIGF. - Post-analytical interpretation of pre-eclampsia risk outcome assessed. - Programme suitable for Lab and POCT applications. - Liquid human samples require no pre-analytical preparation. For more information: https://www.weqas.com/services/eqa/pre-eclampsia/ or contact@weqas.com
Product groups Health care / medical devices
Testing fields Medical analysis
Technical details
Test item Tested property Testing method
Human EDTA plasma sFlt-1 Routine testing methods (recommended)
PIGF Routine testing methods (recommended)
sFlt-1/PlGF Ratio Routine testing methods (recommended)
Pre-Eclampsia Risk Routine testing methods (recommended)
Aims of the PT scheme
Target group of participants The programme is suitable for both Laboratory and POCT applications.
Linked to specific legislation / standards ISO/IEC 17043
Additional, subsidiary aims validation of testing methods
Number of participants
Accredited or otherwise reviewed by a 3rd party

Accredited by UKAS on the basis of ISO/IEC 17043

Operation is commissioned / requested by
Fees and frequency
Participation fee https://www.weqas.com/participantzone/subscription-charges/
Regularly operated Yes (Frequency: Monthly. Samples: 3 x 0.5mL)
Year of first operation 2020
Contact details of the PT provider
Provider Contact person
Unit 6, Parc Ty Glas
CF14 5DU Cardiff
United Kingdom

Phone: 44 (0) 2920 314750
Web: http://www.weqas.com http://www.weqas.com
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884
Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom, Mr Savvas Xystouris. Mr Savvas Xystouris.
Any questions or problems? Please contact us at eptis@bam.de.
Application version: 1.23-SNAPSHOT.20230502124635-7925ae379a631fc1ececff45d2921c8db38877d5